China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE), with the unit price and other details yet to be disclosed. This move marks a significant step for the company as it seeks to expand its reach and funding in the global market.
Focus on Next-Generation Immunotherapies
Since its inception in 2016, Hanx Bio has been dedicated to the development of next-generation immunotherapies. The company leverages its expertise in structural biology, translational medicine, and clinical development to create innovative treatments for various diseases.
Innovative Pipeline and Clinical Stage Candidates
Hanx Bio boasts an innovative pipeline that includes three clinical stage candidate drugs for oncology: HX009, HX301, and HX044. Additionally, the company has seven preclinical stage candidate drugs, which include antibody drug conjugates, bispecific antibodies, and monoclonal antibodies targeting the autoimmune and tumor markets. HX008, another drug in their portfolio, has been licensed to a biopharma focused on cancer therapy.
Core Product HX009 and Other Candidates’ Clinical Progress
Core product HX009, a bifunctional fusion protein targeting PD-1 and SIRPα, is currently undergoing a China Phase Ib study in advanced melanoma and a China Phase I/II study in recurrent or refractory (r/r) EBV+ non-Hodgkin lymphoma. HX009 has already concluded Phase I trials in Australia and China.
HX301, a multi-target kinase inhibitor targeting CSF1R, ARK5, FLT-3, and CDK4/6, is in Phase I study in China, with plans for a Phase II study combined with temozolomide in glioblastoma. Lastly, HX044, a CD47–SIRPα-targeted product, has initiated a Phase I/IIa study in advanced solid tumors in Austria, with a clinical filing under review in China.-Fineline Info & Tech
Leave a Reply